Cyclerion Therapeutics, Inc. (CYCN) reports that its board of directors has set the close of business on September 4, 2026 as the record date for a previously announced distribution of contingent value rights (CVRs) to holders of its common stock and Series A Preferred Stock. The CVR Distribution is tied to Cyclerion’s planned merger with Korsana Biosciences, Inc..
Cyclerion outlines numerous risks that could affect completion and timing of the merger and any potential payments under the CVRs, including failure to obtain shareholder approval, financing, regulatory and Nasdaq listing risks, and potential legal proceedings. Stockholders are directed to review the Form S-4 and related proxy statement/prospectus for detailed information about the merger and CVRs.
Cyclerion Therapeutics, Inc. (CYCN) reported that its Chief Financial Officer, Rhonda M. Chicko, exercised stock options for 25,000 shares of common stock on August 14, 2026 at an exercise price of $2.355 per share, paid in cash. These options, granted on August 7, 2025 under the 2019 Equity Incentive Plan and originally vesting over time, had all remaining vesting accelerated by the board on July 17, 2026. After the exercise, Chicko directly holds 25,018 shares of common stock and no remaining options from this specific grant.
Cyclerion Therapeutics, Inc. reported that President and Chief Executive Officer Regina Margaret Graul exercised an employee stock option for 55,849 shares of common stock at $3.30 per share on August 14, 2026. The option, originally granted on August 5, 2024 under the 2019 Equity Incentive Plan, had its remaining unvested portion fully accelerated by the board on July 17, 2026. The exercise was completed as a cashless exercise, with options to purchase 48,629 shares forfeited to Cyclerion as payment of the full exercise price, and the reported option position reduced to zero following the transaction.
ADAR1 Capital Management, LLC and Daniel Schneeberger report beneficial ownership of Cyclerion Therapeutics, Inc. common stock. Private investment funds managed by ADAR1 hold 298,757 shares of common stock, representing 7.0% of the class. This percentage is based on 4,256,284 shares outstanding as of June 30, 2026, as reported by Cyclerion. Voting and dispositive power over these shares is reported as shared, with no sole voting or dispositive power for either reporting person.
Balyasny Asset Management L.P. and related entities report beneficial ownership of common stock of Cyclerion Therapeutics, Inc. The group, including BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, is deemed to beneficially own 317,511 shares of Cyclerion common stock.
This position represents approximately 7.33% of the class, based on 4,330,314 shares outstanding as of May 10, 2026. The reporting persons have sole voting and sole dispositive power over 317,511 shares and no shared voting or dispositive power. The shares are held directly by Atlas Diversified Master Fund, Ltd., a Cayman Islands exempted company that is an investment management client of BAM and is entitled to dividends and sale proceeds.
Cyclerion Therapeutics is pursuing a merger with Korsana Biosciences under an Agreement and Plan of Merger and Reorganization dated April 1, 2026. A two-step structure would make Korsana a wholly owned subsidiary of Cyclerion through sequential mergers into Cyclerion’s merger subsidiaries.
The communication highlights forward-looking statements about KRSA-028, Korsana’s THETA platform and pipeline for neurodegenerative diseases, the expected closing timing, future Nasdaq listing and ticker, and anticipated clinical data. It also lists extensive risks, including failure to obtain shareholder and regulatory approvals, completion of related financing, maintaining Nasdaq listing, integration challenges, funding needs, and potential legal proceedings. Investors are urged to review the Form S-4 and proxy statement/prospectus filed with the SEC, and the notice stresses that this is not an offer to sell securities or a proxy solicitation.
Cyclerion Therapeutics, Inc. describes a proposed two-step merger with Korsana Biosciences, Inc. under an Agreement and Plan of Merger and Reorganization. First, Cariboos Merger Sub Corp. will merge into Korsana, making Korsana a wholly owned subsidiary of Cyclerion; Korsana will then merge into Cariboos Merger Sub II, LLC as part of the same overall transaction.
The company includes extensive forward‑looking statements about the merger, Korsana’s KRSA-028 program and THETA platform, future Nasdaq listing details, and expected timing, and highlights numerous risks that could affect completion and outcomes. Investors are directed to review the Form S-4 registration statement containing the proxy statement/prospectus and other SEC filings for detailed information before making any voting or investment decisions.
Cyclerion Therapeutics describes a proposed Merger Agreement under which two wholly owned Cyclerion subsidiaries would merge with Korsana Biosciences, leaving Korsana as a wholly owned subsidiary before completing a second-step merger. The communication emphasizes that the transaction remains subject to conditions, including Cyclerion stockholder approval, regulatory clearances and completion of a financing transaction.
The text focuses on forward-looking statements about the combined company’s drug pipeline, leadership, regulatory path and Nasdaq listing, and lists extensive risks that could delay, alter or prevent completion of the merger or realization of anticipated benefits. It also clarifies that the communication is not an offer to sell securities or a solicitation of proxies and directs investors to Cyclerion’s Form S-4 and related proxy statement/prospectus filed with the SEC for detailed information.
Cyclerion Therapeutics, Inc. reported cash and cash equivalents of $1.391 million and total assets of $6.93 million as of June 30, 2026, with stockholders’ equity of $5.087 million. For the first half of 2026 it generated no revenue and recorded a net loss of $4.932 million, versus $1.753 million a year earlier.
The company has concluded that substantial doubt exists about its ability to continue as a going concern, expecting existing cash to fund operations only until the anticipated closing of its planned merger with Korsana Biosciences. The merger would make Korsana’s neurodegeneration portfolio the primary business, supported by a concurrent Korsana financing of approximately $380.0 million.
Pre-merger Cyclerion shareholders are expected to receive contingent value rights tied to potential monetization of legacy assets, including the praliciguat license with Akebia and the Tisento equity stake. Research and development spending has been curtailed, and efforts on the treatment-resistant depression program have been suspended due to cash constraints.
Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. describe progress on their proposed reverse merger and major leadership additions at Korsana. Korsana appoints Matthew Leoni, M.D., as Chief Medical Officer, Gan Wei, Ph.D., as Chief Technical Officer, and Heidi Henson to its Board as Chair of the Audit Committee.
The companies continue to expect the merger to close in the third quarter of 2026, after which the combined company plans to operate as Korsana Biosciences, Inc. and trade on Nasdaq under ticker “KRSA.” Korsana is advancing KRSA-028, a THETA™-enabled therapeutic candidate for Alzheimer’s disease, with Phase 1 healthy volunteer data expected in mid-2027 and interim proof-of-concept data on amyloid plaque clearance anticipated by late 2027 or early 2028.
The communication emphasizes that a Form S-4 registration statement containing a proxy statement/prospectus has been filed for the transaction and urges Cyclerion investors and stockholders to read it and related SEC filings, while clarifying that this communication is not an offer or solicitation for any securities.